bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 29, 2024
Abstract
Therapeutic
proteins
and
peptides
have
revolutionized
modern
biomedicine.
However,
the
large
size
complex
structure
of
these
macromolecules
preclude
their
oral
administration,
greatly
limiting
applications
in
patient
care.
Biochemical
degradation
gastrointestinal
tract,
mucus,
cellular
barrier
are
major
obstacles
to
development.
Small
extracellular
vesicles
(sEVs)
natural
nano
lipid
serving
as
essential
vehicles
for
intercellular
communication.
sEVs
resistant
biochemical
degradation,
permeable
mucus
barriers,
can
penetrate
barriers.
thus
considered
next-generation
with
potential
peptide/protein
drug
delivery.
Herein,
we
report
use
milk-derived
delivery
achieve
successful
highly
efficient
two
therapeutic
GLP-1
receptor
agonists,
semaglutide
tirzepatide.
We
showed
that
tirzepatide
be
efficiently
loaded
onto
vitro,
gavage
semaglutide-loaded
or
tirzepatide-loaded
effectively
lower
blood
glucose
levels
db/db
mouse
models.
This
study
demonstrates
is
a
platform
technology
peptide
opens
new
avenue
therapeutics
Cancer Cell International,
Год журнала:
2025,
Номер
25(1)
Опубликована: Янв. 27, 2025
Theranostics
is
a
way
of
treating
illness
that
blends
medicine
with
testing.
Specific
characteristics
should
be
present
in
the
best
theranostic
agents
for
cancer:
(1)
drugs
safe
and
non-toxic;
(2)
they
able
to
treat
cancer
selectively;
(3)
build
up
only
cancerous
tissue.
Liposomes
(LPs)
are
one
most
efficient
drug
delivery
methods
based
on
nanotechnology.
Stealth
LPs
commercial
have
recently
had
an
impact
treatment.
Using
valuable
information
from
each
imaging
technique,
along
multimodality
functionality
liposomal
therapeutic
agents,
makes
them
very
appealing
personalized
monitoring
how
well
working
against
vivo
predicting
therapies
will
work.
On
other
hand,
their
use
as
nanoparticle
systems
currently
research
development
phase.
Nanoscale
system
innovation
has
made
LP-nanoparticle
hybrid
structures
useful
combining
methods.
LP-hybrid
nanoparticles
better
at
killing
cells
than
LP
counterparts,
making
excellent
options
vitro
applications.
Hybrid
liposomes
(HLs)
could
used
future
carriers
find
targets.
This
would
combine
features
synthetic
biological
systems.
Overarchingly,
this
article
provided
comprehensive
overview
many
types
detection,
therapy,
analysis.
An
evaluation
pros
cons
HLs
detection
treatment
also
been
conducted.
The
study
included
recent
significant
We
conclude
by
outlining
potential
benefits
drawbacks
approach
concurrent
different
malignancies,
its
prospects.
Journal of Nanobiotechnology,
Год журнала:
2025,
Номер
23(1)
Опубликована: Фев. 10, 2025
Alzheimer's
disease
(AD)
is
a
distinctive
form
of
dementia
characterized
by
age-related
cognitive
decline
and
memory
impairment.
A
key
hallmark
AD
the
irreversible
overaccumulation
beta-amyloid
(Aβ)
in
brain,
associated
with
neuroinflammation
neuronal
death.
Although
Aβ
clearance
immunoregulation
have
been
major
therapeutic
strategies
for
AD,
highly
selective
transport
across
blood–brain
barrier
(BBB)
negatively
affects
delivery
efficacy
drugs
without
ability
to
cross
BBB.
In
this
review,
we
discuss
potential
lipid-based
nanoparticles
(LBNs)
as
promising
vehicles
drug
treatment.
LBNs,
composed
phospholipid
mono-
or
bilayer,
attracted
attention
due
their
exceptional
cellular
penetration
capabilities
loading
capabilities,
which
also
facilitate
cargo
transcytosis
Recent
advances
development
engineering
LBNs
overcome
existing
limitations
current
clinical
approaches
treatment
addressing
off-target
effects
low
efficacy.
Here,
review
pathways
BBB,
well
various
types
therapy,
including
exosomes,
liposomes,
solid
lipid
(SLNs),
nanostructured
carriers
(NLCs),
elucidate
properties,
preparation
methodologies,
efficacy,
thereby
offering
innovative
avenues
novel
translation
therapy.
Naturally
occurring
extracellular
vesicles
(EVs)
and
synthetic
nanoparticles
like
liposomes
have
revolutionized
precision
diagnostics
medicine.
EVs
excel
in
biocompatibility
cell
targeting,
while
offer
enhanced
drug
loading
capacity
scalability.
The
clinical
translation
of
is
hindered
by
challenges
including
low
yield
heterogeneity,
whereas
face
rapid
immune
clearance
limited
targeting
efficiency.
To
bridge
these
gaps,
biomimetic
(SVs)
emerged
as
innovative
platforms,
combining
the
advantageous
properties
liposomes.
This
review
emphasizes
critical
aspects
EV
biology,
such
mechanisms
EV-cell
interaction
source-dependent
functionalities
modulation,
tissue
regeneration,
informing
SV
engineering.
We
reviewed
a
broad
array
SVs,
with
focus
on
lipid
bilayered
functionalized
proteins.
These
include
cell-derived
nanovesicles,
protein-functionalized
liposomes,
hybrid
vesicles.
By
addressing
current
highlighting
opportunities,
this
aims
to
advance
SVs
for
transformative
biomedical
applications.
Extracellular
vesicles
(EVs)
are
critical
mediators
of
intercellular
communication,
carrying
bioactive
cargo
and
displaying
diverse
surface
components
that
reflect
their
cellular
origins
functions.
The
EV
surface,
composed
proteins,
lipids,
glycocalyx
elements,
plays
a
pivotal
role
in
targeting
recipient
cells,
mediating
biological
interactions,
enabling
selective
delivery.
This
review
comprehensively
examined
the
molecular
architecture
surfaces,
linking
biogenesis
to
functional
diversity,
highlights
therapeutic
diagnostic
potential
diseases
such
as
cancer
cardiovascular
disorders.
Additionally,
we
explore
emerging
applications
EVs,
including
machine-learning-assisted
analysis,
chemical
integration,
cross-system
combinations.
also
discusses
some
key
challenges
clinical
translation
EV-related
technologies.
Biomacromolecules,
Год журнала:
2024,
Номер
25(11), С. 7015 - 7057
Опубликована: Окт. 18, 2024
Biomedical
polymers
play
a
key
role
in
preventing,
diagnosing,
and
treating
diseases,
showcasing
wide
range
of
applications.
Their
unique
advantages,
such
as
rich
source,
good
biocompatibility,
excellent
modifiability,
make
them
ideal
biomaterials
for
drug
delivery,
biomedical
imaging,
tissue
engineering.
However,
conventional
suffer
from
poor
degradation
Pharmaceutics,
Год журнала:
2025,
Номер
17(2), С. 238 - 238
Опубликована: Фев. 12, 2025
Metabolic
diseases
like
obesity
and
diabetes
are
on
the
rise,
therapies
with
biomacromolecules
(such
as
proteins,
peptides,
antibodies,
oligonucleotides)
play
a
crucial
role
in
their
treatment.
However,
these
drugs
traditionally
injected.
For
patients
chronic
(e.g.,
metabolic
diseases),
long-term
injections
accompanied
by
inconvenience
low
compliance.
Oral
administration
is
preferred,
but
delivery
of
challenging
due
to
gastrointestinal
barriers.
In
this
article,
we
introduce
available
biomacromolecule
for
treatment
diseases.
The
barriers
oral
drug
strategies
overcome
also
explored.
We
then
discuss
alleviating
defects,
including
glucose
metabolism,
lipid
energy
such
insulin,
glucagon-like
peptide-1
receptor
agonists,
proprotein
convertase
subtilisin/kexin
type
9
inhibitors,
fibroblast
growth
factor
21
analogues,
peptide
YY
analogues.
